Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety of an investigational intravenous
iron (ferric carboxymaltose [FCM]) or an equal dose of iron dextran and explore the mechanism
of hypophosphatemia following administration of FCM or that of an equal dose of iron dextran
when treating women with iron deficiency anemia due to heavy uterine bleeding (HUB).
Phase:
Phase 2
Details
Lead Sponsor:
American Regent, Inc. Luitpold Pharmaceuticals
Treatments:
Dextrans Ferric Compounds Iron Iron-Dextran Complex